AGEN (Agenus) Buyback Yield % : -49.87 (As of Dec. 13, 2024)

View and export this data going back to 2000. Start your Free Trial

What is Agenus Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Agenus's current buyback yield was -49.87%.

Agenus Buyback Yield % Historical Data

The historical data trend for Agenus's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agenus Buyback Yield % Chart

Agenus Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Buyback Yield %

Get a 7-Day Free Trial

-5.45

-28.83

-26.98

-13.26

-39.38

Agenus Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Buyback Yield %	Get a 7-Day Free Trial															-18.89	-12.22	-28.20	-2.25	-22.81

Competitive Comparison of Agenus's Buyback Yield %

For the Biotechnology subindustry, Agenus's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agenus's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agenus's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Agenus's Buyback Yield % falls into.

Agenus Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Agenus's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (-4.566	+	133.157)	/	326.5022346
	=	-39.38%

Agenus's annualized Buyback Yield for the quarter that ended in Sep. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	6.776)	*	4	/	118.834896
	=	-22.81%

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Sep. 2024) data.

Agenus Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Agenus's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Agenus Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (NAS:AGEN) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

AJ8:Germany

Address

3 Forbes Road, Lexington, MA, USA, 02421

Website

https://www.agenusbio.com

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Executives

Garo H Armen	officer: Chairman & CEO	3 FORBES ROAD, LEXINGTON MA 02421
Ulf Wiinberg	director
Steven J O'day	officer: Chief Medical Officer	2344 BANYAN DRIVE, LOS ANGELES CA 90049
Christine M Klaskin	officer: VP Finance	3 FORBES ROAD, LEXINGTON MA 02421
Adam Krauss	officer: Chief Legal Officer	139 GRANIT STREET, MEDFIELD MA 02052
Susan B Hirsch	director	280 OLD SOMERSET ROAD, WATCHUNG NJ 07069
Paul N Clark	director	5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Incyte Corp	10 percent owner	1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Alex Duncan	officer: Chief Technology Officer	3 FORBES ROAC, LEXINGTON MA 02421
Christian Cortis	officer: See Remarks	3 FORBES ROAD, LEXINGTON MA 02421
Evan Kearns	officer: V.P. and General Counsel	AGENUS INC., 3 FORBES ROAK, LEXINGTON MA 02421
Jennifer Buell	officer: Chief Operating Officer	3 FORBES ROAD, LEXINGTON MA 02421
Allison M Jeynes-ellis	director	FLAT 52, WILLIAM HUNT MANSIONS, LONDON X0 SW13 8HT
Wadih Jordan	director	ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010
Brian Corvese	director	C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010